About Twelve Bio
Twelve Bio is a company based in Copenhagen (Denmark) founded in 2019 by Stefano Stella and Guillermo Montoya was acquired by Ensoma in January 2023. Twelve Bio has raised $2.57 million across 2 funding rounds from investors including Ensoma. The company has 10 employees as of December 31, 2021. Twelve Bio offers products and services including Engenious Platform. Twelve Bio operates in a competitive market with competitors including Senti Biosciences, Poseida Therapeutics, ADARx Pharmaceuticals, CRISPR Therapeutics and Aldevron, among others.
- Headquarter Copenhagen, Denmark
- Employees 10 as on 31 Dec, 2021
- Founders Stefano Stella, Guillermo Montoya
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ensoma Aps
-
Annual Revenue
Not available
-
Net Profit
-$412.66 K (USD)-63as on Dec 31, 2022
-
EBITDA
-$493.27 K (USD)-57as on Dec 31, 2022
-
Total Equity Funding
$2.57 M (USD)
in 2 rounds
-
Latest Funding Round
$2.57 M (USD), Seed
Sep 18, 2020
- Investors
-
Employee Count
10
as on Dec 31, 2021
-
Acquired by
Ensoma
(Jan 05, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Twelve Bio
Twelve Bio offers a comprehensive portfolio of products and services, including Engenious Platform.
Platform that combines delivery and DNA editing for disease treatments.
Funding Insights of Twelve Bio
Twelve Bio has successfully raised a total of $2.57M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2.57 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Twelve Bio
Twelve Bio has secured backing from 1 investor. Prominent investors backing the company include Ensoma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool
|
Locked | Locked | Locked |
Investor details for Twelve Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Twelve Bio
Investment portfolio details for Twelve Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Twelve Bio
Detailed financials for Twelve Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Twelve Bio Comparisons
Peer comparison for Twelve Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Twelve Bio
Twelve Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Poseida Therapeutics, ADARx Pharmaceuticals, CRISPR Therapeutics and Aldevron, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts
|
|
| Locked | Locked | Locked |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing.
|
|
| Locked | Locked | Locked |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| Locked | Locked | Locked |
Therapeutics for molecular-level cancer treatment are developed.
|
Detailed competitors of Twelve Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Twelve Bio
Complete news archive for Twelve Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Twelve Bio
Twelve Bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Twelve Bio is headquartered in Copenhagen, Denmark.
Stefano Stella is the current CEO of Twelve Bio. They have also founded this company.
Twelve Bio is a funded company, having raised a total of $2.57M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Twelve Bio is 10.
Twelve Bio was established in 2019 as a spin-off from the Montoya group in Copenhagen, Denmark. Focus is placed on CRISPR-Cas12a, a protein that functions as a biological tool for detecting and modifying DNA sequences to generate new variants. Diagnostics and therapeutics are created using this technology. Support has been provided by organizations including the BioInnovation Institute, Novo Nordisk Fonden, and Novo Holdings. Operations center on biotechnology applications in healthcare.
Twelve Bio's top competitors include CRISPR Therapeutics, Senti Biosciences and Poseida Therapeutics.
Twelve Bio offers Engenious Platform.
Twelve Bio has 1 investor. Key investors include Ensoma.
The valuation of Twelve Bio is $6.93M as of Sep 2020.